US/UK/Canada

Share

Quotes

In spearheading our adoption of Medidata Detect, we're not only reinforcing our commitment to data quality and patient safety, but we're also embracing a pivotal enhancement to our existing technology stack. Our partnership with Medidata now extends beyond the realms of Rave® EDC, CTMS, and eTMF, illustrating a significant step in our long-term strategy to advance clinical trial efficiency through innovation.
Michael Mendoza, Executive Director of eClinical Technology and Biometrics, TFS HealthScience
We are thrilled to be the first CRO implementing Medidata’s Detect platform, which addresses many data inefficiencies the industry experiences today. Using a centralized data management system will enhance data quality, risk management, and decision-making, fast-tracking clinical trials for clients and the availability of drugs for patients.
Dr. Bassem Saleh, Chief Executive Officer, TFS HealthScience
At Medidata, we’re collaborating with our 2,300+ global customers to accelerate clinical trials by developing new, scalable data experiences that improve quality, maximize efficiency, and better support patients. Medidata Detect will give TFS HealthScience a competitive advantage with AI-driven insights and task automation that reduce the time to high-quality data and bring operational teams closer, eliminating redundancies and aligning processes across the organization.
Tom Doyle, Chief Technology Officer, Medidata
Pick a time period -
Tags ( Active)

Demonstrating strong customer focus and therapeutic expertise, TFS CRO has been awarded new Covid-19 studies.

TFS is working in collaboration with sponsors, at an unprecedented pace. Our operational teams are participating in various studies, targeting coronavirus disease patients or analyzing the real world evidence to bring treatments to COVID-19 patients faster. TFS is continuously recognized for agility as well as the knowledge and experience of our teams. In-depth expertise in the field of internal medicine as well as strong presence in Spain allow TFS to partner with customers on four more trials on Covid-19. The studies total up to more than 3300 patients in 17 sites covering full a

TFS forms partnership to conduct a global RWE study on Covid-19 pandemic.

TFS joins Observational Health Data Sciences and Informatics (OHDSI) community in a COVID-19 virtualstudy-a-thon (March 26-29) to inform healthcare decision-making in response to the current globalpandemic. With the increasing availability of real-world COVID-19 data worldwide the main purpose ofthe event is to generate immediate real-world evidence on prioritized questions shared by nationalgovernments, public health agencies, health-related institutions, and community members; and todesign COVID-19-specific studies that can be validated and available to run when such data is

TFS presents TrialOnline - digital solution for patient retention and data collection as an example of a successful industry partnership.

TFS attends ADCM Conference to present a TrialOnline ePRO – a custom patient retention tool developed in successful partnership between a CRO, EDC vendor and pharma. Patient retention represents an important challenge in some therapeutic areas. Many clinical trials are at risk a risk of low patient retention putting study at jeopardy, may be destined to fail due to a low patient retention. In example, the prevalence of chronic psoriasis in Western industrialized countries is around 2% (>30M people). Most treatments have side effects that may lead patients to withdrawn the treatment,

TFS seminar Secrets to Biotech Success brings together industry stakeholders recognizing a strategic partnership as the foundation of the biotech success.

On September 19th, TFS hosted a seminar in Medicon Village starting a much needed discussion about the changes impacting the biopharmaceutical industry. Representatives from the biotech, academic and investor community came together to share their unique business perspective.A significant and increasing portion of biopharmaceutical R&D worldwide is currently created by small and midsize biotechnology, medical device and medical technology companies. On the other hand, the biotechnology industry is also facing challenges. It’s no longer enough to create products that are innovative, safe and

There are no items matching the current filter
There are no more items matching the current filter
Back to top